Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of intranasal oxytocin on neural response to facial emotions in healthy adults as measured by functional MRI: A systematic review.Psychiatry research. Neuroimaging · 2018Pooled it
- Oxytocin increases eye gaze in schizophrenia.Schizophrenia research · 2019Trial
- Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Intranasal Oxytocin Selectively Modulates Large-Scale Brain Networks in Humans.Brain connectivity · 2017Trial
- A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.Journal of clinical psychopharmacology · 2017Trial
- Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.Psychological medicine · 2017Trial
- Neuropeptidergic systems in psychiatric disorders.Frontiers in endocrinology · 2025Review
- Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration.International journal of nanomedicine · 2025Review
- Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia.Schizophrenia bulletin · 2023Review
- The role of the oxytocin system in the resilience of patients with breast cancer.Frontiers in oncology · 2023Review
- Mathematical model and artificial intelligence for diagnosis of Alzheimer's disease.European physical journal plus · 2023Article
- Review
- Effect of Intranasal Oxytocin on Resting-state Effective Connectivity in Schizophrenia.Schizophrenia bulletin · 2022Article
- A Randomization Permutation Test for Single Subject Mediation.Evaluation & the health professions · 2022Article
- Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.Biomedicines · 2022Review
- Effects of Oxytocin on Social Comparisons in Intergroup Situations.Brain sciences · 2021Article
- Peripheral oxytocin is inversely correlated with cognitive, but not emotional empathy in schizophrenia.PloS one · 2020Article
- Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
- Effects of Intranasal Oxytocin on Emotion Recognition in Korean Male: A Dose-Response Study.Psychiatry investigation · 2018Article
- Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression?European journal of rheumatology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired facial emotion recognition is a core deficit in schizophrenia. Oxytocin has been shown to improve social perception in patients with schizophrenia; however, the effect of oxytocin on the neural activity underlying facial emotion recognition has not been investigated. This study was aimed to assess the effect of a single dose of intranasal oxytocin on brain activity in patients with schizophrenia using an implicit facial emotion-recognition paradigm. Sixteen male patients with schizophrenia and 16 age-matched healthy male control subjects participated in a randomized, double-blind, placebo-controlled crossover trial at Seoul National University Hospital. Delivery of a single dose of 40 IU intranasal oxytocin and the placebo was separated by 1 week. Drug conditions were compared by performing a region of interest (ROI) analysis of the bilateral amygdala on responses to the emotion recognition test. It was found that nasal spray decreased amygdala activity for fearful emotion and increased activity for happy faces. Further, oxytocin elicited differential effects between the patient and control groups. Intranasal oxytocin attenuated amygdala activity for emotional faces in patients with schizophrenia, whereas intranasal oxytocin significantly increased amygdala activity in healthy controls. Oxytocin-induced BOLD signal changes in amygdala in response to happy faces was related to attachment style in the control group. Our result provides new evidence of a modulatory effect of oxytocin on neural response to emotional faces for patients with schizophrenia. Future studies are needed to investigate the effectiveness of long-term treatment with intranasal oxytocin on neural activity in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.